| Title | Impact of WHI conclusions and ACOG guidelines on clinical practice. | | Author(s) | Gass M | | Institution | Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0526, USA. | | Source | Int J Fertil Womens Med 2003 May-Jun; 48(3):106-10; discussion 137-8. | | MeSH | Breast Neoplasms
Estrogen Replacement Therapy
Estrogens, Conjugated (USP)
Female
Humans
Medroxyprogesterone 17-Acetate
Osteoporosis, Postmenopausal
Practice Guidelines
Randomized Controlled Trials
Research Support, Non-U.S. Gov't
Societies, Medical
Women's Health
| | Abstract | This past July, the community of physicians practicing obstetrics/gynecology and women's medicine was startled by a paper in the Journal of the American Medical Association, which reported data from one arm of the Women's Health Initiative (WHI). The major finding was that the group of subjects undergoing treatment with combined HRT in the form of Prempro (0.625 mg/day conjugated equine estrogens (CEE) + 2.5 mg/day medroxyprogesterone acetate) was found to have increased risk of breast cancer and no apparent cardiac benefit. Although several benefits were considered, the likely result to be realized by 8 years, interim findings by the study's safety committee at 5 years were deemed sufficiently troubling to stop this arm of the trial at 5.2 years. Reaction was mixed. This paper places findings into a clinical perspective and considers their effect on the practice guidelines of relevant professional organizations. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 12839140 |
|
